Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Pharmacology of Infectious Diseases
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1451083

Anti-HSV-1 agents, An update

Provisionally accepted
Wenwen Lv Wenwen Lv 1Lei Zhou Lei Zhou 1*Jia Wu Jia Wu 1*Jishuai Cheng Jishuai Cheng 1Yongzhong Duan Yongzhong Duan 1*Qian Wen Qian Wen 2*
  • 1 Kunming Medical University, Kunming, China
  • 2 Walvax Biotechnology Co., Ltd., Kunming, Yunnan, China

The final, formatted version of the article will be published soon.

    Herpes simplex virus type I (HSV-1) is a member of the α -herpesvirus subfamily, capable of causing herpes simplex virus keratitis (HSK), herpes labialis, and herpes simplex virus encephalitis (HSE). HSV-1 is well known for its lytic infection in the primary sites and then establishing latentcy in the sensory neuronal ganglia, and occasionally causes recurrent infection. To date, no commercially available vaccines have been approved, and the anti-HSV-1 drugs such as specific or non-specific nucleotide (nucloside) analogs, helicase-primase inhibitors (HPIs) have become the main clinical agents for the treatment of HSV-1 infection, despite the challenges of resistance. The development of new anti-HSV-1 compounds or therapies is the key to address the issue of resistance. This review provides an update on the progress made over approximately sixty years regarding anti-HSV-1 agents while also highlighting future perspectives for controlling HSV-1 infection.

    Keywords: HSV-1, antiviral, agents, Immunomodulation, Herpes virus

    Received: 18 Jun 2024; Accepted: 27 Nov 2024.

    Copyright: © 2024 Lv, Zhou, Wu, Cheng, Duan and Wen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Lei Zhou, Kunming Medical University, Kunming, China
    Jia Wu, Kunming Medical University, Kunming, China
    Yongzhong Duan, Kunming Medical University, Kunming, China
    Qian Wen, Walvax Biotechnology Co., Ltd., Kunming, Yunnan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.